A Medical Analogy	The Diagnostics	The Aetiology oo	Research Agenda

Monitoring Competitiveness Taking Stock and Outlining Further Steps

C. Osbat based on work with S. Formai, S. Özyurt, T. Karlsson, M. Rau-Goehring

The opinions expressed here are the authors' only and do not reflect those of the ECB or the Eurosystem

Frankfurt, CompNet Workshop, 2 April 2012

	A Medical Analogy	The Diagnostics	The Aetiology	Research Agenda
Outline				



- Outcomes and Drivers
- Our Working Definition
- 2 A Medical Analogy
- 3 The Diagnostics
 - List of Indicators
 - Results
 - Price/Non Price Competitiveness
- 4 The Aetiology
 - Bayesian Model Selection
 - Variable List
- 5 Research Agenda

Motivation
A Medical Analogy
The Diagnostics
The Aetiology
Research A

•>
0000
000
00
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
00

Competitiveness: Outcomes and Drivers

- Need an independent in-depth view on the outcomes and drivers of international competitiveness.
- Offer a synthetic assessment of past and current outcomes.
- Directly relevant for formulating and evaluating policies.
- Competitiveness is a fuzzy concept, no consensus definition: so far we restricted our working definition to trade outcomes.
- We want to relate the outcomes we identify ("success stories" vs "problem areas") to structural and macroeconomic factors.

No Consensus Definition: we look at trade outcomes

- Often focus on price and cost factors only (ULC, Real Exchange Rates, etc).
- More thorough analysis from firm-level data (but "matching problem" when moving from micro to macro results on competitiveness).
- Our working assumption: International competitiveness = ability to compete in international markets = trade outcomes.
- Manifestation of high productivity ⇒ more sustainable growth and higher living standards.
- Analogy with firm competitiveness: firms compete for market share and in attracting capital, countries compete for export shares and FDI inflows.

	A Medical Analogy	The Diagnostics	The Aetiology oo	Research Agenda
A Medic	al Analogy			

It makes sense to separate outcomes and drivers to aid policy formulation and evaluation: a medical analogy

- Outcomes: Diagnostics.
 - Measurable outcomes in trade and FDI.
 - Capturing many dimensions: e.g. extensive and intensive margins, product differentiation, price and non-price competitiveness.
- Drivers: Aetiology.
 - Linking each outcome to structural and macroeconomic factors
- Policy Formulation: Therapy.
 - Extracting policy recommendations from the link between outcomes and drivers.
 - Without forgetting policy evaluation! ("Health Policy?")

Motivation

The Indicators We Used So Far

We looked at 48 countries, including all G20 and EU countries and additional advanced economies, % change in last 2 years and average annual % change, 2005-2010.

We did a cluster analysis on:

- Overall export Performance
 - Percentage change in world trade share of exports (both manufacturing and services).
- Openness and integration in production networks
 - Relative trade intensity in intermediates (Balassa index in BEC).
 - Exports openness.
- Export diversification and sophistication
 - Extensive margin (number of trade relationships).
 - Export sophistication (associated with a country's specialization pattern).
- FDI
 - Net FDI inflows over GDP.
 - World share of FDI inflows.

Motivation

The Diagnostics

The Aetiology

Research Agenda

A Peek At the Results (preliminary!)

Overall export performance					Openness and integration in production networks									Export diversification and sophistication								FDI												
% change in manufacturing export market share					9 B int	6 chan alassa ermed	the x for goods	% change in export/GDP			% change in export extensive margin				% ghange in expy				% change in net inflows/GDP				% change in ne ouflows/GDP											
	9	SR		SR MR		MR		SR IV		MR		SR	MR			SR		MR		SR	1	MR		SR	1	MR	SR		MR		SR		N	И
	SA	27.2	CN	7.33	CN 7	.13	IN	7.80	FI	2.16	AU	1.24	LV	9.28	LT	4.33	LV	7.11	LV	10.0	RO	3.45	RO	2.39	FI	37.4	FI	12.5	ΜХ	3.12	NZ			
	IN	9.22	SA		SA		CN		IN		ΗK		IE		HU		IE		MX		CY		LV		DE	4.07	AT	4.88	BE		AT			
	KR		IN		IN		BR		MT		AT		RO		KR		RO		RO		IL.		IL.		LT	0.73	NL		IL.	0.36	MT			
	CN		SK		нк		RO		RO		RO		LT		US		РТ		IL		SA		LT		LV		GR	0.29	FI		BE			
	ID		LV		ID		SA		AU		JP		EE		IN		LT	3.45	LT	4.63	SG	1.26	CY		SG		LT		LU		MX			
	SG	5.22	AR		SG		AR		RU		DE	0.14	мх	1.70	сү		PL		BG		мх		нк	0.50	NL		ID		SK		CN			
	мх		LT		ZA		ΜТ		JP		BE		сү		ιv		HU		CN		PL		CN		ES		LV		ES		IL.			
	AR		PL.		СН		PL.		NO	0.18	CY		нк		JP		LU		BE		NO		PL		NO		ES		DE		BR			
	RO		RO		BR		SG		SG		MT		нu		IE		cz		FI		LV		IE		LU		DE		IE		DE			
	нк		cz	0.83	AR		RU	3.08	нк		τU		BG		AU		τU		τu		KR		BG		cz		NO		нк		NL			
	JP	0.67	KR		AU		cz		LV		ES		NL		DE	2.72	KR		РТ		LT		τu		BE		τυ		NL		IN			
	сн		IL.		US		LV		BE		СН		PL		EE		AT		IN		BG		NO		ID		РΤ		PL		PL			
	IL		SI		CA -C	.78	LU		KR		ZA		мт		нк		SK		cz		FR		cz		СҮ	-0.24	BE		cz	-0.20	NO			
	IE		СҮ		BE		СН		BR		IN		ES		NL		CN		PL	2.37	BE		MT		мт		MT		SE		IT			
	AU		τυ		IL.		нк		BG		FI		cz		υк		BE		CA		TU		SA		EE		SG		RU		LU			
	SK		ID		TU		KR		MX		DK		UK		SA		ES		SK		UK		KR		нк		IL		US		EE			
	NL		EE		LU		FI		CA		IT		DK		СН		мх	1.14	AT		СН		SK		BR		IN		AU		KR			
	ZA	-3.57	BG		IE		IE		AR	-0.86	AR		SK	-1.49	MX		FR		KR		нк		СН		CN		сү		IT		сү			

- < ロ > < 同 > < 回 > < 回 > = 3

Motivation A Medical Analogy The Diagnostics The Actiology Research Agen

Competitiveness (VERY Preliminary!)



(a) Allocation of HS-6 sectors



(b) Decomposition of German trade balance



(c) Decomposition of Italian trade balance

- We collected 50+ variables measuring both structural and macroeconomic factors.
- We regress each "diagnostic indicator" on all variables using Bayesian model selection/averaging (BMS).
- Only just began on the cross-section of 2005-2010 averages.
- This modelling approach can provide, for each indicator:
 - An evaluation of the importance of each variable in determining the various dimensions of the outcomes.
 - The average impact, across all models, of each variable.
 - Predicted outcomes of each country: a positive residual then indicates "super-success".
- Do residuals predict future growth?
- Do different variables support e.g. intensive or extensive margin, or trade vs FDI?

otivation A Medical Analogy The Diagnostics **The Aetiology** Research Agenda

An Indicative Variable List

- Price indicators: Real effective exchange rate, volatility of exchange rates, unit labour costs, [...].
- Non-Price indicators: Rigidity of Employment, R&D expenditure, Road Density, Internet Users, Tariff Rates, [...].
- Structural indicators: Market capitalization of listed companies, Control of corruption, schooling indicators, Time required to enforce a contract, [...].
- Macro indicators: Domestic credit to private sector, Public Debt/GDP, CPI inflation, Investment/GDP, [...].
- Pure structural controls: Population, surface area, population growth, urban population, dummy for ex-union with UK, Spain, Russia, [...].

Research Agenda

- First Deliverable: a diagnostic toolbox \Rightarrow need input on:
 - More indicators.
 - Methodology, robustness, enhancing cluster analysis. Should we use principal components to get synthetic indicators?
- Second Deliverable: a causal analysis
 - Also more indicators.
 - A systematic investigation of the link between the various dimensions of competitive performance and structural vs macro policies.
- Third Deliverable: a "Materia Medica"? (More ambitious).

A Medical Analogy

The Diagnostics

The Aetiology

Research Agenda (continued)

Another central theme: linking micro-meso-macro analysis:

- Micro: firm-level analysis can zoom in on what structures/policies support internationalisation activities/success on international markets.
- Meso: Sectoral data are the basis of indicators of e.g. extensive margins, price/non price competitiveness, which can directly be translated into aggregate measures (e.g. contribution to trade balance).
- Macro: the level at which Central Banks operate mostly.
- We have already started in two ways:
 - Linking outcome indicators (some from sectoral data) and macroeconomic drivers.
 - Translating sectoral price/non price competitiveness into trade balance contributions.